MPD: Phenotype measures mapped to MP:0001790, abnormal immune system physiology

Phenotype measures associated with ontology term
MP:0001790 'abnormal immune system physiology'

All measures in this list are mapped to the ontology descendants of MP:0001790. None are mapped to MP:0001790 directly.

This MP term has been mapped to these MPD phenotype measurements to help users find relevant data. It should be noted that MPD measurements typically have a mixture of high-end, low-end and "normal" readings.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year

Auwerx1:195	Auwerx1	cell signaling molecule detection	high-fat diet	blood interferon gamma (INF gamma) amount [pg/mL] inf_gamma 111374 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:197	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-18 (IL-18) amount [pg/mL] il_18 111376 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:199	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-6 (IL-6) amount [pg/mL] il_6 111378 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:201	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-10 (IL-10) amount [pg/mL] il_10 111380 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:203	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-15 (IL-15) amount [pg/mL] il_15 111382 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:205	Auwerx1	cell signaling molecule detection	high-fat diet	blood monocyte chemoattractant protein 1 (MCP1) amount [pg/mL] mcp1 111384 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:207	Auwerx1	cell signaling molecule detection	high-fat diet	blood macrophage inflammatory protein 1 alpha subunit (MIP1 alpha) amount [pg/mL] mip1_alpha 111386 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:209	Auwerx1	cell signaling molecule detection	high-fat diet	blood macrophage inflammatory protein 1 beta subunit (MIP1 beta) amount [pg/mL] mip1_beta 111388 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:211	Auwerx1	cell signaling molecule detection	high-fat diet	blood regulated on activation, normal T cell expressed and secreted (RANTES) protein amount [pg/mL] rantes 111390 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:213	Auwerx1	cell signaling molecule detection	high-fat diet	blood tumor necrosis factor alpha (TNF alpha) amount [pg/mL] tnf_alpha 111392 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Benavides1:1	Benavides1	genotype assessment	(none)	Gpr84 allele deletion in exon 2 (0=yes, 1=no) [designation] Gpr84 48201	inbred w/CC8	58	both	6wks		2013

Boon1:11	Boon1	body weight	influenza A (H5N1) virus	change in body weight, post-infection [%] bw_change 46911 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:21	Boon1	health assessment	influenza A (H5N1) virus	survival (days to death, max 30) [d] survival 46921 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:31	Boon1	health assessment	influenza A (H5N1) virus	susceptibility to viral infection (0=susceptible, 1=resistant) [designation] resistance 46931 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Bopp1:1	Bopp1	health assessment	Plasmodium berghei	survival, post-infection [d] survival 36401	inbred	31	both	8-12wks	N=4	2010

Bopp1:2	Bopp1	health assessment	Plasmodium berghei	terminal body temperature, post-infection [°C] body_temp 36402	inbred	31	both	8-12wks	N=4	2010

Bopp1:3	Bopp1	health assessment	Plasmodium berghei	percentage of parasite-infected erythrocytes in blood [%] parasitemia 36403	inbred	31	both	8-12wks	N=4	2010

Bopp1:4	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in brain relative to all organs tested [%] luciferase_brain 36404	inbred	28	both	8-12wks	N=2	2010

Bopp1:5	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in spleen relative to all organs tested [%] luciferase_spleen 36405	inbred	28	both	8-12wks	N=2	2010

Bopp1:6	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in lungs relative to all organs tested [%] luciferase_lungs 36406	inbred	28	both	8-12wks	N=2	2010

Bopp1:7	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in liver relative to all organs tested [%] luciferase_liver 36407	inbred	28	both	8-12wks	N=2	2010

Brinkmeyer1:1	Brinkmeyer1	body weight	Theiler's murine encephalomyelitis virus	body weight, post infection [g] bw 64401 day 0 day 2 day 4 day 6 day 8 day 10 day 14 day 17 day 22 day 27 (6 more)...	CC	5	both	4wks	N=5	2017

Brinkmeyer1:17	Brinkmeyer1	health assessment	Theiler's murine encephalomyelitis virus	clinical score (0=normal, 6=moribund), post infection [score] clin_score 64417 day 0 day 2 day 4 day 6 day 8 day 12 day 18 day 24 day 29 day 34 (6 more)...	CC	5	both	4wks	N=5	2017

Brinkmeyer1:33	Brinkmeyer1	RNA expression profiling	Theiler's murine encephalomyelitis virus	TMEV transcript abundance (normalized), post infection TMEV 64433 day 7 day 28	CC	4	both	4wks	N=1	2017

Brinkmeyer1:35	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of seconds spent grooming, 10 min test, post infection wk 3 (manual assessment) [s] grooming 64435	CC	5	both	4wks	N=2	2017

Brinkmeyer1:36	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of times mouse reared, 10 min test, post infection wk 3 (manual assessment) [n] activity_rearing 64436	CC	5	both	4wks	N=2	2017

Brinkmeyer1:37	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	horizontal movement latency, 30 min test, post infection wk 3 [s] horiz_latency 64437 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:39	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of horizontal movements (beam breaks), 30 min test, post infection wk 3 [n] horiz_activity 64439 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:41	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	horizontal distance traveled, 30 min test, post infection wk 3 [cm] horiz_distance 64441 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:43	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent moving horizontally, 30 min test, post infection wk 3 [s] horiz_time 64443 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:45	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	horizontal movement velocity, 30 min test, post infection wk 3 [cm/s] horiz_velocity 64445 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:47	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of vertical plane entries, 30 min test, post infection wk 3 [n] vert_activity 64447 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:49	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of vertical plane episodes, 30 min test, post infection wk 3 [n] vert_episodes 64449 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:51	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent vertical, 30 min test, post infection wk 3 [s] vert_time 64451 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:53	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent resting, 30 min test, post infection wk 3 [s] resting 64453 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:55	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of center entries, 30 min test, post infection wk 3 [n] center_entries 64455 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:57	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent in center, 30 min test, post infection wk 3 [s] center_time 64457 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:59	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent in periphery, 30 min test, post infection wk 3 [s] periphery_time 64459 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:61	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of steps included in analysis as measured by DigiGait, post infection day 27, forelimb [n] num_steps_fore 64461 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:63	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of steps included in analysis as measured by DigiGait, post infection day 27, hindlimb [n] num_steps_hind 64463 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:65	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of swing phase (no paw contact with belt) as measured by DigiGait, post infection day 27, forelimb [s] swing_dur_fore 64465 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:67	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of swing phase (no paw contact with belt) as measured by DigiGait, post infection day 27, hindlimb [s] swing_dur_hind 64467 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:69	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in air as measured by DigiGait, post infection day 27, forelimb [%] swing_stride_fore 64469 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:71	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in air as measured by DigiGait, post infection day 27, hindlimb [%] swing_stride_hind 64471 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:73	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of braking phase as measured by DigiGait, post infection day 27, forelimb [s] brake_dur_fore 64473 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:75	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of braking phase as measured by DigiGait, post infection day 27, hindlimb [s] brake_dur_hind 64475 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:77	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in braking phase as measured by DigiGait, post infection day 27, forelimb [%] brake_stride_fore 64477 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:79	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in braking phase as measured by DigiGait, post infection day 27, hindlimb [%] brake_stride_hind 64479 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:81	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in braking phase as measured by DigiGait, post infection day 27, forelimb [%] brake_stance_fore 64481 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:83	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in braking phase as measured by DigiGait, post infection day 27, hindlimb [%] brake_stance_hind 64483 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:85	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of propulsion phase as measured by DigiGait, post infection day 27, forelimb [s] propel_dur_fore 64485 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:87	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of propulsion phase as measured by DigiGait, post infection day 27, hindlimb [s] propel_dur_hind 64487 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:89	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in propulsion phase as measured by DigiGait, post infection day 27, forelimb [%] propel_stride_fore 64489 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:91	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in propulsion phase as measured by DigiGait, post infection day 27, hindlimb [%] propel_stride_hind 64491 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:93	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in propulsion phase as measured by DigiGait, post infection day 27, forelimb [%] propel_stance_fore 64493 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:95	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in propulsion phase as measured by DigiGait, post infection day 27, hindlimb [%] propel_stance_hind 64495 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:97	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in any contact with treadmill belt as measured by DigiGait, post infection day 27, forelimb [%] stance_stride_fore 64497 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:99	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in any contact with treadmill belt as measured by DigiGait, post infection day 27, hindlimb [%] stance_stride_hind 64499 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:101	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of swing phase time to stance phase time as measured by DigiGait, post infection day 27, forelimb [ratio] stance_swing_fore 64501 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:103	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of swing phase time to stance phase time as measured by DigiGait, post infection day 27, hindlimb [ratio] stance_swing_hind 64503 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:105	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of one complete stride for one paw (equal to stance and swing durations) as measured by DigiGait, post infection day 27, forelimb [s] stride_dur_fore 64505 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:107	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of one complete stride for one paw (equal to stance and swing durations) as measured by DigiGait, post infection day 27, hindlimb [s] stride_dur_hind 64507 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:109	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of times each second (cadence) that a paw takes a complete stride as measured by DigiGait, post infection day 27, forelimb [n/s] stride_freq_fore 64509 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:111	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of times each second (cadence) that a paw takes a complete stride as measured by DigiGait, post infection day 27, hindlimb [n/s] stride_freq_hind 64511 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:113	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	spatial length that a paw traverses through a given stride as measured by DigiGait, post infection day 27, forelimb [cm] stride_length_fore 64513 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:115	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	spatial length that a paw traverses through a given stride as measured by DigiGait, post infection day 27, hindlimb [cm] stride_length_hind 64515 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:117	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length variability as measured by DigiGait, post infection day 27, forelimb [cm] stride_length_var_fore 64517 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:119	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length variability as measured by DigiGait, post infection day 27, hindlimb [cm] stride_length_var_hind 64519 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:121	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length coefficient of variation as measured by DigiGait, post infection day 27, forelimb [%] stride_length_CV_fore 64521 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:123	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length coefficient of variation as measured by DigiGait, post infection day 27, hindlimb [%] stride_length_CV_hind 64523 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:125	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	angle that paw makes with long axis of direction of motion of mouse as measured by DigiGait, post infection day 27, forelimb [deg] paw_angle_fore 64525 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:127	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	angle that paw makes with long axis of direction of motion of mouse as measured by DigiGait, post infection day 27, hindlimb [deg] paw_angle_hind 64527 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:129	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw angle for set of strides recorded as measured by DigiGait, post infection day 27, forelimb [deg] paw_angle_SD_fore 64529 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:131	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw angle for set of strides recorded as measured by DigiGait, post infection day 27, hindlimb [deg] paw_angle_SD_hind 64531 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:133	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal paw area as measured by DigiGait, post infection day 27, forelimb [cm²] paw_area_max_fore 64533 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:135	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal paw area as measured by DigiGait, post infection day 27, hindlimb [cm²] paw_area_max_hind 64535 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:137	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw area for set of strides recorded as measured by DigiGait, post infection day 27, forelimb [cm²] paw_area_SD_fore 64537 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:139	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw area for set of strides recorded as measured by DigiGait, post infection day 27, hindlimb [cm²] paw_area_SD_hind 64539 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:141	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of forelimb stepping to fore limb stepping frequency (coordination metric) as measured by DigiGait, post infection day 27, forelimb [ratio] gait_symmetry_fore 64541 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:143	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of forelimb stepping to hind limb stepping frequency (coordination metric) as measured by DigiGait, post infection day 27, hindlimb [ratio] gait_symmetry_hind 64543 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:145	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during braking phase as measured by DigiGait, post infection day 27, forelimb [cm²/s] max_area_break_fore 64545 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:147	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during braking phase as measured by DigiGait, post infection day 27, hindlimb [cm²/s] max_area_break_hind 64547 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:149	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during propulsion phase as measured by DigiGait, post infection day 27, forelimb [cm²/s] max_area_propuls_fore 64549 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:151	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during propulsion phase as measured by DigiGait, post infection day 27, hindlimb [cm²/s] max_area_propuls_hind 64551 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:153	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	overlap extent of ipsilateral fore and hind paws as measured by DigiGait, post infection day 27, forelimb [cm] overlap_distance_fore 64553 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:155	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	overlap extent of ipsilateral fore and hind paws as measured by DigiGait, post infection day 27, hindlimb [cm] overlap_distance_hind 64555 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:157	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	extent of overlap between ipsilateral fore and hind paws during full stance (balance metric) as measured by DigiGait, post infection day 27, forelimb [cm] paw_placement_fore 64557 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:159	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	extent of overlap between ipsilateral fore and hind paws during full stance (balance metric) as measured by DigiGait, post infection day 27, hindlimb [cm] paw_placement_hind 64559 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:161	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	gait variability metric as measured by DigiGait, post infection day 27, forelimb ataxia_coefficient_fore 64561 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:163	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	gait variability metric as measured by DigiGait, post infection day 27, hindlimb ataxia_coefficient_hind 64563 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:165	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through transverse midline of mouse (kinetics metric) as measured by DigiGait, post infection day 27, forelimb [cm] midline_distance_fore 64565 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:167	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through transverse midline of mouse (kinetics metric) as measured by DigiGait, post infection day 27, hindlimb [cm] midline_distance_hind 64567 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:169	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through axis of mouse (kinetics metric) as measured by DigiGait, post infection day 27, forelimb [cm] axis_distance_fore 64569 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:171	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through axis of mouse (kinetics metric) as measured by DigiGait, post infection day 27, hindlimb [cm] axis_distance_hind 64571 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:173	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	perpendicular distance between centroids of either set of axial paws during peak stance as measured by DigiGait, post infection day 27 [cm] stance_width 64573 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:175	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stance width coefficient of variation as measured by DigiGait, post infection day 27 [%] stance_width_CV 64575 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:177	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of left and right stance durations as measured by DigiGait, post infection day 27 [ratio] stance_factor 64577 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:179	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride width variability as measured by DigiGait, post infection day 27 [cm] stride_width_var 64579 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:181	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	angle made between left and right paws as a function of stride length and stance width as measured by DigiGait, post infection day 27 [deg] step_angle 64581 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:183	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	step angle variability (standard deviation of step angle for set of strides recorded) as measured by DigiGait, post infection day 27 [deg] step_angle_SD 64583 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:185	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	step angle coefficient of variation as measured by DigiGait, post infection day 27 [%] step_angle_CV 64585 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:187	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	length of forelimb steps as measured by foot print analysis, post infection [cm] length_fore 64587 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:194	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	width of forelimb steps as measured by foot print analysis, post infection [cm] width_fore 64594 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:201	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	length of hindlimb steps as measured by foot print analysis, post infection [cm] length_hind 64601 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:208	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	width of hindlimb steps as measured by foot print analysis, post infection [cm] width_hind 64608 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:215	Brinkmeyer1	rotarod	Theiler's murine encephalomyelitis virus	time to fall from accelerating rotarod, post infection wk 7 [s] rotarod 64615 trial 1 trial 2 trial 3 trial 4 trial 5 trial 6 trial 7 trial 8 trial 9	CC	5	both	4wks	N=2	2017

Cowell1:1	Cowell1	hormone quantification	Staphylococcus aureus	fold-change in serum IL-6 levels 24h post-infection compared to controls [ratio] IL6 49001	inbred	13	f	8wks	N=3	2012

Cowell1:2	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from peritoneal fluid 24h post-infection (x 10³) (CFU/mL) [log(n/mL)] peritoneal_CFU 49002	inbred	13	f	8wks	N=5	2012

Cowell1:3	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from kidney 24h post-infection (CFU/g) [log(n/g)] kidney_CFU 49003	inbred	13	f	8wks	N=6	2012

Cowell1:4	Cowell1	health assessment	Staphylococcus aureus	median survival time, max time 104h [h] median_survival 49004	inbred	13	f	8wks	N=11	2012

Cowell1:5	Cowell1	health assessment	Staphylococcus aureus	percent survival, max time 104h [%] pct_survival 49005	inbred	13	f	8wks	N=11	2012

Dietrich1:1	Dietrich1	in vitro assay	Bacillus anthracis lethal toxin	susceptibility to Bacillus anthracis (0=susceptible, 1=resistant) [designation] anthrax_lethal_toxin 1501	inbred	50	f	6-8wks*		1998

Donahue7:1	Donahue7	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 41601	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue7:2	Donahue7	immunoglobulin quantification	(none)	immunoglobulin G (plasma IgG) [µg/mL] IgG 41602	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue7:3	Donahue7	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 41603	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue8:1	Donahue8	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 41701	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Donahue8:2	Donahue8	immunoglobulin quantification	(none)	immunoglobulin G (plasma IgG) [µg/mL] IgG 41702	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Donahue8:3	Donahue8	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 41703	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Eumorphia7:1	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin M (serum IgM) [µg/mL] IgM 29601	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:2	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G3 (serum IgG3) [µg/mL] IgG3 29602	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:3	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G1 (serum IgG1) [µg/mL] IgG1 29603	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:4	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G2b (serum IgG2b) [µg/mL] IgG2b 29604	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:5	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G2a (serum IgG2a) [µg/mL] IgG2a 29605	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:6	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin A (serum IgA) [µg/mL] IgA 29606	inbred	6	both	9-12wks	N=5	2008

Farmer1:1	Farmer1	histopathology	(none)	severity of lesions in cecum [score] CecumSeverity 11301	QTL population		both	6wks	N=206	2001

Farmer1:2	Farmer1	histopathology	(none)	hyperplasia of cecum [score] CecumHyperplasia 11302	QTL population		both	6wks	N=206	2001

Farmer1:3	Farmer1	histopathology	(none)	ulceration in cecum [score] CecumUlceration 11303	QTL population		both	6wks	N=206	2001

Farmer1:4	Farmer1	histopathology	(none)	percentage of cecum damaged area [%] CecumDA 11304	QTL population		both	6wks	N=206	2001

Farmer1:5	Farmer1	histopathology	(none)	sum of cecum severity, hyperplasia, ulceration and damaged area scores [score] CecumTotalScore 11305	QTL population		both	6wks	N=206	2001

Farmer1:6	Farmer1	histopathology	(none)	percentage of proximal colon damaged area [%] ProxDA 11306	QTL population		both	6wks	N=206	2001

Farmer1:7	Farmer1	histopathology	(none)	severity of lesions in proximal colon [score] ProxSeverity 11307	QTL population		both	6wks	N=206	2001

Farmer1:8	Farmer1	histopathology	(none)	hyperplasia of proximal colon [score] ProxHyperplasia 11308	QTL population		both	6wks	N=206	2001

Farmer1:9	Farmer1	histopathology	(none)	ulceration in proximal colon [score] ProxUlceration 11309	QTL population		both	6wks	N=206	2001

Farmer1:10	Farmer1	histopathology	(none)	percentage of damaged area in mid colon [%] MidDA 11310	QTL population		both	6wks	N=206	2001

Farmer1:11	Farmer1	histopathology	(none)	severity of lesions in mid colon [score] MidSeverity 11311	QTL population		both	6wks	N=206	2001

Farmer1:12	Farmer1	histopathology	(none)	hyperplasia of mid colon [score] MidHyperplasia 11312	QTL population		both	6wks	N=206	2001

Farmer1:13	Farmer1	histopathology	(none)	ulcers and crypts frequency score [score] MidUlceration 11313	QTL population		both	6wks	N=206	2001

Farmer1:14	Farmer1	histopathology	(none)	percentage of damaged area in distal colon [%] DistalDA 11314	QTL population		both	6wks	N=206	2001

Farmer1:15	Farmer1	histopathology	(none)	severity of lesions in distal colon [score] DistalSeverity 11315	QTL population		both	6wks	N=206	2001

Farmer1:16	Farmer1	histopathology	(none)	hyperplasia of distal colon [score] DistalHyperplasia 11316	QTL population		both	6wks	N=206	2001

Farmer1:17	Farmer1	histopathology	(none)	ulceration in distal colon [score] DistalUlceration 11317	QTL population		both	6wks	N=206	2001

Farmer1:18	Farmer1	histopathology	(none)	proximal colon score [score] ProximalColon 11318	QTL population		both	6wks	N=206	2001

Farmer1:19	Farmer1	histopathology	(none)	middle colon score [score] MiddleColon 11319	QTL population		both	6wks	N=206	2001

Farmer1:20	Farmer1	histopathology	(none)	distal colon score [score] DistalColon 11320	QTL population		both	6wks	N=206	2001

Farmer1:21	Farmer1	histopathology	(none)	total score [score] ColonTotalScore 11321	QTL population		both	6wks	N=206	2001

Farmer1:29	Farmer1	hormone quantification	(none)	lgG2a antibodies against escherichia coli membrane antigens [ng/ml] IgG2aantiECM 11329	QTL population		both	6wks	N=206	2001

Farmer1:30	Farmer1	hormone quantification	(none)	levels of total lgG reactivity against escherichia coli membrane (ECM) antigens [ng/ml] IgGantiECM 11330	QTL population		both	6wks	N=206	2001

Farmer1:31	Farmer1	hormone quantification	(none)	secretory IgA in collected blood [ng/ml] IgA 11331	QTL population		both	6wks	N=206	2001

Farmer1:32	Farmer1	hormone quantification	(none)	levels of IgA secreted in feces [ng/ml] IgAfeces 11332	QTL population		both	6wks	N=206	2001

Farmer1:33	Farmer1	immune cell quantification	(none)	percentage of Interleukin 12 in collected blood [%] IL12 11333	QTL population		both	6wks	N=206	2001

Ferris1:1	Ferris1	body weight	influenza A (H1N1) virus	body weight pre-infection (day 0) [g] bw_D0 47601	CC pre w/par	163	f	8-16wks	N=1	2012

Ferris1:2	Ferris1	body weight	influenza A (H1N1) virus	percent change in body weight, day 4 post-infection [%] bw_change 47602	CC pre w/par	163	f	8-16wks	N=1	2012

Ferris1:3	Ferris1	health assessment	influenza A (H1N1) virus	clinical score, day 4 post-infection (score 0-4) [score] clinical_score 47603	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:5	Ferris1	health assessment	influenza A (H1N1) virus	susceptibility to viral infection index (0=susceptible; 1= resistant) [score] susceptibility_index 47605	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:6	Ferris1	in vitro assay	influenza A (H1N1) virus	viral replication log titer, day 4 post-infection (lung) [n] titer 47606	CC pre w/par	162	f	8-16wks	N=1	2012

Ferris1:7	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced airway inflammation, day 4 post-infection (score 0-3) [score] airway_inflam 47607	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:8	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced airway neutrophils, day 4 post-infection (score 0-3) [score] airway_neut 47608	CC pre w/par	140	f	8-16wks	N=1	2012

Ferris1:9	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced airway damage, day 4 post-infection (score 0-3) [score] airway_damage 47609	CC pre w/par	160	f	8-16wks	N=1	2012

Ferris1:10	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced vascular inflammation (lung), day 4 post-infection (score 0-3) [score] vascular_inflam 47610	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:11	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced alveolar inflammation, day 4 post-infection (score 0-3) [score] alveolar_inflam 47611	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:12	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced alveolar damage, day 4 post-infection (score 0-3) [score] alveolar_damage 47612	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:13	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced pulmonary edema, day 4 post-infection (score 0-3) [score] pulmonary_edema 47613	CC pre w/par	138	f	8-16wks	N=1	2012

GMC20:2	GMC20	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 56902 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:4	GMC20	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 56904 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=5	2018

GMC20:6	GMC20	immunoglobulin quantification	(none)	immunoglobulin G1 (plasma IgG1) [µg/mL] IgG1 56906 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=4	2018

GMC20:8	GMC20	immunoglobulin quantification	(none)	immunoglobulin G2a (plasma IgG2a) [µg/mL] IgG2a 56908 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:10	GMC20	immunoglobulin quantification	(none)	immunoglobulin G2b (plasma IgG2b) [µg/mL] IgG2b 56910 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=4	2018

GMC20:12	GMC20	immunoglobulin quantification	(none)	immunoglobulin G3 (plasma IgG3) [µg/mL] IgG3 56912 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:14	GMC20	immunoglobulin quantification	(none)	immunoglobulin E (plasma IgE) [ng/mL] IgE 56914 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:16	GMC20	autoantibody quantification	(none)	anti-DNA autoantibodies (plasma) aDNA 56916 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=7	2018

GMC20:18	GMC20	autoantibody quantification	(none)	rheumatoid factor (plasma RF) RF 56918 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=7	2018

Graham1:1	Graham1	body weight	West Nile virus	body weight, post infection [g] bw 63301 day 0 day 3 day 6 day 8 day 9 day 10 day 11 day 12 day 13 day 14 (4 more)...	CC RIX	5	m	8-10wks	N=12	2015

Graham1:15	Graham1	health assessment	West Nile virus	clinical score (0=healthy, 1=lethargic, 2=altered gait, 3=no movement, 4=moribund), post infection [score] clin_score 63315 day 0 day 3 day 6 day 8 day 9 day 10 day 11 day 12 day 13 day 14 (4 more)...	CC RIX	5	m	8-10wks	N=12	2015

Graham1:29	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD4+ in brain, post infection [%] CD4_brain 63329 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:33	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD4+ in spleen, post infection [%] CD4_spleen 63333 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:37	Graham1	immune cell quantification	West Nile virus	percentage of CD4+ T cells that are Foxp3+ in the brain, post infection [%] Treg_brain 63337 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:41	Graham1	immune cell quantification	West Nile virus	percentage of CD4+ T cells that are Foxp3+ in the spleen, post infection [%] Treg_spleen 63341 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:45	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD8+ in brain, post infection [%] CD8_brain 63345 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:49	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD8+ in spleen, post infection [%] CD8_spleen 63349 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:53	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are NS4b+ in brain, post infection [%] NS4b_brain 63353 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:57	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are NS4b+ in spleen, post infection [%] NS4b_spleen 63357 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:61	Graham1	immunoglobulin quantification	West Nile virus	virus-specific IgM in serum, post infection [ng/mL] WNV_IgM 63361 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:65	Graham1	RNA expression profiling	West Nile virus	virus in brain, fold change compared to matched control, post infection WNV_brain 63365 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:68	Graham1	RNA expression profiling	West Nile virus	virus in kidney, fold change compared to matched control, post infection WNV_kidney 63368 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:72	Graham1	RNA expression profiling	West Nile virus	virus in spleen, fold change compared to matched control, post infection WNV_spleen 63372 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:76	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in brain, fold change compared to matched control, post infection Ifnb1_brain 63376 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:79	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in kidney, fold change compared to matched control, post infection Ifnb1_kidney 63379 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:83	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in spleen, fold change compared to matched control, post infection Ifnb1_spleen 63383 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:87	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in brain, fold change compared to matched control, post infection Ifit1_brain 63387 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:90	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in kidney, fold change compared to matched control, post infection Ifit1_kidney 63390 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:94	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in spleen, fold change compared to matched control, post infection Ifit1_spleen 63394 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham2:3	Graham2	colony observation	SARS-CoV	body weight loss and survival score (1=0-5% loss, 2=5-15% loss, 3=greater than 15% loss and death) [score] weight_score 113787	CC RIX	117	f	8-10wks		2021

Graham2:6	Graham2	in vitro assay	SARS-CoV	lung viral load titer (log10(x+1)), post infection [log(n)] log_titer 113790 post infection: day 2 day 4	CC RIX	111	f	8-10wks		2021

Graham3:49	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IL17_pos 113840	CC RIX	102	m	8-10wks	N=4	2021

Graham3:50	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IGNg_pos 113841	CC RIX	102	m	8-10wks	N=4	2021

Graham3:52	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IL17_pos 113843	CC RIX	102	m	8-10wks	N=4	2021

Graham3:53	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IFNg_pos 113844	CC RIX	102	m	8-10wks	N=4	2021

Gros1:1	Gros1	in vitro assay	Candida albicans	kidney fungal load 48h post-infection, colony-forming units (log₁₀ CFU per kidney) [log(n)] fungal_load 38501	inbred	23	f	8-12wks	N=9	2011

Gros1:2	Gros1	in vitro assay	Candida albicans	susceptibility to C. albicans based on fungal load (0=susceptible; 1=resistant) [designation] susceptibility 38502	inbred	23	f	8-12wks	N=9	2011

Gros1:3	Gros1	genotype assessment	(none)	C5 allele (0=deficient, 1=sufficient) [designation] C5_allele 38503	inbred	36	f	8-12wks	N=6	2011

Gros2:1	Gros2	microscopy	Plasmodium chabaudi	percentage of parasite-infected erythrocytes in blood [%] parasitemia 49301	inbred	25	both	8-10wks	N=5	2012

Gros2:2	Gros2	health assessment	Plasmodium chabaudi	percent survival post-infection (max=21d) [%] survival 49302	inbred	25	both	8-10wks	N=5	2012

Gros2:3	Gros2	health assessment	Plasmodium chabaudi	response to infection (0=susceptible, 0.5=intermediate, 1=resistant) [designation] resistance 49303	inbred	25	both	8-10wks	N=5	2012

Haston1:3	Haston1	bronchoalveolar lavage assessment	radiation	percentage of macrophages in bronchoalveolar lavage [%] BAL_mac 48803	inbred	26	both	15-36wks	N=6	2012

Haston1:4	Haston1	bronchoalveolar lavage assessment	radiation	percentage of lymphocytes in bronchoalveolar lavage [%] BAL_lym 48804	inbred	26	both	15-36wks	N=6	2012

Haston1:5	Haston1	bronchoalveolar lavage assessment	radiation	percentage of neutrophils in bronchoalveolar lavage [%] BAL_neut 48805	inbred	26	both	15-36wks	N=6	2012

Haston1:6	Haston1	histopathology	radiation	average number of mast cells per mm² of lung tissue [n] mast_cells 48806	inbred	25	both	15-36wks	N=6	2012

Haston1:7	Haston1	histopathology	radiation	inflammation index (0=no alveolitis, 6=severe alveolitis) [score] alveolitis 48807	inbred	26	both	15-36wks	N=6	2012

Jax2:3	Jax2	MHC haplotype tissue typing	(none)	major histocompatibility complex (MHC) H2 haplotype [designation] h2_haplotype 9303 categorical	inbred		both			2000

Mahler1:2	Mahler1	histopathology	(none)	cecum assessment, first Principal Component CecumPC1 12102	QTL population		both	6wks	N=102	2002

Mahler1:3	Mahler1	histopathology	(none)	proximal colon assessment, first Principal Component ProxPC1 12103	QTL population		both	6wks	N=102	2002

Mahler1:4	Mahler1	histopathology	(none)	middle colon assessment, first Principal Component MidPC1 12104	QTL population		both	6wks	N=102	2002

Mahler1:5	Mahler1	histopathology	(none)	distal colon assessment, first Principal Component DistPC1 12105	QTL population		both	6wks	N=102	2002

Mahler1:6	Mahler1	histopathology	(none)	ulceration (score 0-4, increasing severity), first Principal Component Ulceration-PC1 12106	QTL population		both	6wks	N=102	2002

Mahler1:7	Mahler1	histopathology	(none)	ulceration (score 0-4, increasing severity), second Principal Component Ulceration-PC2 12107	QTL population		both	6wks	N=102	2002

Mills1:5	Mills1	apoptosis assessment	(none)	early apoptotic splenocytes [%] early_apoptotic 25205 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mills1:11	Mills1	apoptosis assessment	(none)	late apoptotic splenocytes [%] late_apoptotic 25211 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mills1:17	Mills1	apoptosis assessment	(none)	all apoptotic splenocytes [%] all_apoptotic 25217 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mrug1:3	Mrug1	histopathology	(none)	cholangitis severity (score 0-4, increasing severity) 0 = no/minimal inflammation, 4=severe and extensive cholangiohepatitis [score] Cholangitis 17503	QTL population		both	10d	N=230	2005

Noll1:26	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin M (serum IgM) area under curve (AUC) post-infection [AUC] IgM 112602 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:31	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G1 (serum IgG1) area under curve (AUC) post-infection [AUC] IgG1 112607 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:36	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G2a plus G2c (serum IgG2a pooled with IgG2c) area under curve (AUC) post-infection [AUC] IgG2ac 112612 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:41	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G2b (serum IgG2b) area under curve (AUC) post-infection [AUC] IgG2b 112617 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=3	2020

Noll1:46	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G3 (serum IgG3) area under curve (AUC) post-infection [AUC] IgG3 112622 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:51	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	total immunoglobulin G (serum IgG) area under curve (AUC) post-infection [AUC] Total_IgG 112627 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	44	f	8-12 wks	N=3	2020

Peters1:25	Peters1	coagulation test	(none)	fibrinogen [mg/dL] Fib 6225	inbred w/CC7	43	both	10wks	N=10	2001

Powell1:1	Powell1	in vitro assay	Neisseria musculi	oral cavity bacterial colony count (CFU/swab) post inoculation (x 10³) [n] bacterial_load 62801 wk 1 wk 2 wk 3 wk 4 wk 5 wk 6 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12	inbred	8	both	8-16wks	N=12	2018

Rodriguez1:1	Rodriguez1	in vitro assay	(none)	spleen and liver murine cytomegalovirus genome levels (normalized to endogenous b-actin) [ratio] CMV_LEVELS 24101	QTL population		both	8-12wks	N=92	2009

Schughart1:1	Schughart1	body weight	influenza A (H1N1) virus	body weight as percent of baseline [%] pctBW 39301 day 1 day 3 day 7 day 12	inbred	9	both	10-12wks	N=10	2009

Schughart1:5	Schughart1	health assessment	influenza A (H1N1) virus	susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 39305	inbred	9	both	10-12wks	N=11	2009

Schughart2:2	Schughart2	body weight	influenza A (H1N1) virus	body weight as percent of baseline [%] pctbw 49602 day 1 day 3 day 7	BXD w/par	56	f	9-18wks	N=6	2012

Schughart2:6	Schughart2	health assessment	influenza A (H1N1) virus	survival, post-infection [d] survival_days 49606	BXD w/par	56	f	9-18wks	N=6	2012

Schughart2:7	Schughart2	health assessment	influenza A (H1N1) virus	susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 49607	BXD w/par	56	f	9-18wks	N=6	2012

Schughart3:11	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 10 FFU group [%] pctbwA 57111 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred w/CC8	8	both	7-13wks	N=9	2013

Schughart3:31	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 2000 FFU group [%] pctbwB 57131 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred w/CC8	8	both	7-13wks	N=9	2013

Schughart3:51	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 200,000 FFU group [%] pctbwC 57151 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred	2	both	7-13wks	N=12	2013

Schughart3:81	Schughart3	health assessment	influenza A (H3N2) virus	survival, post-infection [d] day_survival 57181 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Schughart3:91	Schughart3	health assessment	influenza A (H3N2) virus	susceptibility to viral infection (0=resistant, 1=susceptible), mortality rate [score] status_day_survival 57191 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Schughart4:11	Schughart4	body weight	(none)	body weight as percent of baseline, control (saline) group [%] pctbw_ctrl 58711 days post-treatment (saline): 1 2 3	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:21	Schughart4	body weight	influenza A (H3N2) virus	body weight as percent of baseline, infected group [%] pctbw_trt 58721 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 30	inbred w/CC8	8	f	8-12wks	N=11	2016

Schughart4:83	Schughart4	in vitro assay	influenza A (H3N2) virus	viral load in lungs (titer, FFU per lung) log10 (x+1) [log(n)] titer_trt 58783 days post-infection: 3 5 8	inbred w/CC8	8	f	8-12wks	N=5	2016

Schughart5:11	Schughart5	body weight	(none)	body weight as percent of baseline [%] pctbw 58811 days post-treatment (saline): 1 2 3	inbred w/CC8	8	f	8-12wks	N=4	2016

Schughart5:21	Schughart5	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 10 FFU group [%] pctbw_trt 58821 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 30	inbred w/CC8	8	f	8-12wks	N=9	2016

Schwartz2:1	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), pre-challenge [%] pctEOS0 9801 pre-test: control OVA-sensitized	inbred	8	m	6-8wks	N=3	2001

Schwartz2:2	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), 24h post-challenge [%] pctEOS24 9802 24h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:3	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), 48h post-challenge [%] pctEOS48 9803 48h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:4	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), 72h post-challenge [%] pctEOS72 9804 72h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:21	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), pre-challenge [%] pctLYM0 9821 pre-test: control OVA-sensitized	inbred	8	m	6-8wks	N=3	2001

Schwartz2:22	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), 24h post-challenge [%] pctLYM24 9822 24h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:23	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), 48h post-challenge [%] pctLYM48 9823 48h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:24	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), 72h post-challenge [%] pctLYM72 9824 72h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:41	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), pre-challenge [%] pctNEUT0 9841 pre-test: control OVA-sensitized	inbred	8	m	6-8wks	N=3	2001

Schwartz2:42	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), 24h post-challenge [%] pctNEUT24 9842 24h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:43	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), 48h post-challenge [%] pctNEUT48 9843 48h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:44	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), 72h post-challenge [%] pctNEUT72 9844 72h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Sundberg2:1	Sundberg2	histopathology	(none)	Alopecia areata diagnosis (score 0=no alopecia, 1=alopecia) [score] alopecia_score 13501	QTL population		both	52wks	N=184	2003

Svenson3:43	Svenson3	coagulation test	(none)	blood fibrinogen [mg/dL] Fib 27343	B6.PWD consomic w/par	23	both	6wks	N=8	2006

Zaytseva1:1	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 1, core fucose with 1 GlcNAc antenna (relative abundance) [%] gp1 110006	CC	111	both	4-140wks	N=3	2018

Zaytseva1:2	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 2, composition not determined (relative abundance) [%] gp2 110007	CC	111	both	4-140wks	N=3	2018

Zaytseva1:3	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 3, composition not determined (relative abundance) [%] gp3 110008	CC	111	both	4-140wks	N=3	2018

Zaytseva1:4	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 4, core fucose with 2 GlcNAc antennae (relative abundance) [%] gp4 110009	CC	111	both	4-140wks	N=3	2018

Zaytseva1:5	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 5, composition not determined (relative abundance) [%] gp5 110010	CC	111	both	4-140wks	N=3	2018

Zaytseva1:6	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 6, core fucose with bisecting GlcNAc and 2 GlcNAc antennae (relative abundance) [%] gp6 110011	CC	111	both	4-140wks	N=3	2018

Zaytseva1:7	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 7, composition not determined (relative abundance) [%] gp7 110012	CC	111	both	4-140wks	N=3	2018

Zaytseva1:8	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 8, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,6-linked core mannose (relative abundance) [%] gp8 110013	CC	111	both	4-140wks	N=3	2018

Zaytseva1:9	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 9, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,3-linked core mannose (relative abundance) [%] gp9 110014	CC	111	both	4-140wks	N=3	2018

Zaytseva1:10	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 10, core fucose with bisecting GlcNAc and 2 GlcNAc antennae, 1 galactose linked to alpha1,6-linked core mannose (relative abundance) [%] gp10 110015	CC	111	both	4-140wks	N=3	2018

Zaytseva1:11	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 11, composition not determined (relative abundance) [%] gp11 110016	CC	111	both	4-140wks	N=3	2018

Zaytseva1:12	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 12, composition not determined (relative abundance) [%] gp12 110017	CC	111	both	4-140wks	N=3	2018

Zaytseva1:13	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 13, composition not determined (relative abundance) [%] gp13 110018	CC	111	both	4-140wks	N=3	2018

Zaytseva1:14	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 14, core fucose with 2 GlcNAc antennae, 2 galactoses (relative abundance) [%] gp14 110019	CC	111	both	4-140wks	N=3	2018

Zaytseva1:15	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 15, composition not determined (relative abundance) [%] gp15 110020	CC	111	both	4-140wks	N=3	2018

Zaytseva1:16	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 16, composition not determined (relative abundance) [%] gp16 110021	CC	111	both	4-140wks	N=3	2018

Zaytseva1:17	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 17a, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,6-linked core mannose, 1 sialic acid (relative abundance) [%] gp17a 110022	CC	111	both	4-140wks	N=3	2018

Zaytseva1:18	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 17b, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,3-linked core mannose, 1 sialic acid (relative abundance) [%] gp17b 110023	CC	111	both	4-140wks	N=3	2018

Zaytseva1:19	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 18, composition not determined (relative abundance) [%] gp18 110024	CC	111	both	4-140wks	N=3	2018

Zaytseva1:20	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 19, composition not determined (relative abundance) [%] gp19 110025	CC	111	both	4-140wks	N=3	2018

Zaytseva1:21	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 20, core fucose with 2 GlcNAc antennae, 2 galactoses, 1 sialic acid (relative abundance) [%] gp20 110026	CC	111	both	4-140wks	N=3	2018

Zaytseva1:22	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 21, composition not determined (relative abundance) [%] gp21 110027	CC	111	both	4-140wks	N=3	2018

Zaytseva1:23	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 22, composition not determined (relative abundance) [%] gp22 110028	CC	111	both	4-140wks	N=3	2018

Zaytseva1:24	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 23, core fucose with 2 GlcNAc antennae, 3 galactoses, 1 sialic acid (relative abundance) [%] gp23 110029	CC	111	both	4-140wks	N=3	2018

Zaytseva1:25	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 24, composition not determined (relative abundance) [%] gp24 110030	CC	111	both	4-140wks	N=3	2018

Zaytseva1:26	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 25, core fucose with 2 GlcNAc antennae, 2 galactoses, 2 sialic acids (relative abundance) [%] gp25 110031	CC	111	both	4-140wks	N=3	2018

Zaytseva2:1	Zaytseva2	glycosylation profile	(none)	IgG1 with bisected N-acetylglucosamine N-glycan structures (relative abundance) [%] mIgG1_B 110032	CC	94	both	20-117wks	N=2	2018

Zaytseva2:2	Zaytseva2	glycosylation profile	(none)	IgG1 with galactosylated N-glycan structures (relative abundance) [%] mIgG1_G 110033	CC	94	both	20-117wks	N=2	2018

Zaytseva2:3	Zaytseva2	glycosylation profile	(none)	IgG1 with agalactosylated N-glycan structures (relative abundance) [%] mIgG1_G0 110034	CC	94	both	20-117wks	N=2	2018

Zaytseva2:4	Zaytseva2	glycosylation profile	(none)	IgG1 with monogalactosylated N-glycan structures (relative abundance) [%] mIgG1_G1 110035	CC	94	both	20-117wks	N=2	2018

Zaytseva2:5	Zaytseva2	glycosylation profile	(none)	IgG1 with digalactosylated N-glycan structures (relative abundance) [%] mIgG1_G2 110036	CC	94	both	20-117wks	N=2	2018

Zaytseva2:6	Zaytseva2	glycosylation profile	(none)	IgG1 with sialylated N-glycan structures (relative abundance) [%] mIgG1_S 110037	CC	94	both	20-117wks	N=2	2018

Zaytseva2:7	Zaytseva2	glycosylation profile	(none)	IgG1 with monosialylated N-glycan structures (relative abundance) [%] mIgG1_S1 110038	CC	94	both	20-117wks	N=2	2018

Zaytseva2:8	Zaytseva2	glycosylation profile	(none)	IgG1 with disialylated N-glycan structures (relative abundance) [%] mIgG1_S2 110039	CC	94	both	20-117wks	N=2	2018

Zaytseva2:9	Zaytseva2	glycosylation profile	(none)	IgG1 with alpha1,3-linked galactose residue N-glycan structures (relative abundance) [%] mIgG1_aGal 110040	CC	94	both	20-117wks	N=2	2018

Zaytseva2:10	Zaytseva2	glycosylation profile	(none)	IgG2 with bisected N-acetylglucosamine N-glycan structures (relative abundance) [%] mIgG2_B 110041	CC	94	both	20-117wks	N=2	2018

Zaytseva2:11	Zaytseva2	glycosylation profile	(none)	IgG2 with galactosylated N-glycan structures (relative abundance) [%] mIgG2_G 110042	CC	94	both	20-117wks	N=2	2018

Zaytseva2:12	Zaytseva2	glycosylation profile	(none)	IgG2 with agalactosylated N-glycan structures (relative abundance) [%] mIgG2_G0 110043	CC	94	both	20-117wks	N=2	2018

Zaytseva2:13	Zaytseva2	glycosylation profile	(none)	IgG2 with monogalactosylated N-glycan structures (relative abundance) [%] mIgG2_G1 110044	CC	94	both	20-117wks	N=2	2018

Zaytseva2:14	Zaytseva2	glycosylation profile	(none)	IgG2 with digalactosylated N-glycan structures (relative abundance) [%] mIgG2_G2 110045	CC	94	both	20-117wks	N=2	2018

Zaytseva2:15	Zaytseva2	glycosylation profile	(none)	IgG2 with sialylated N-glycan structures (relative abundance) [%] mIgG2_S 110046	CC	94	both	20-117wks	N=2	2018

Zaytseva2:16	Zaytseva2	glycosylation profile	(none)	IgG2 with monosialylated N-glycan structures (relative abundance) [%] mIgG2_S1 110047	CC	94	both	20-117wks	N=2	2018

Zaytseva2:17	Zaytseva2	glycosylation profile	(none)	IgG2 with disialylated N-glycan structures (relative abundance) [%] mIgG2_S2 110048	CC	94	both	20-117wks	N=2	2018

Zaytseva2:18	Zaytseva2	glycosylation profile	(none)	IgG2 with alpha1,3-linked galactose residue N-glycan structures (relative abundance) [%] mIgG2_aGal 110049	CC	94	both	20-117wks	N=2	2018

Zaytseva2:19	Zaytseva2	glycosylation profile	(none)	IgG3 with bisected N-acetylglucosamine N-glycan structures (relative abundance) [%] mIgG3_B 110050	CC	95	both	20-117wks	N=2	2018

Zaytseva2:20	Zaytseva2	glycosylation profile	(none)	IgG3 with galactosylated N-glycan structures (relative abundance) [%] mIgG3_G 110051	CC	95	both	20-117wks	N=2	2018

Zaytseva2:21	Zaytseva2	glycosylation profile	(none)	IgG3 with agalactosylated N-glycan structures (relative abundance) [%] mIgG3_G0 110052	CC	95	both	20-117wks	N=2	2018

Zaytseva2:22	Zaytseva2	glycosylation profile	(none)	IgG3 with monogalactosylated N-glycan structures (relative abundance) [%] mIgG3_G1 110053	CC	95	both	20-117wks	N=2	2018

Zaytseva2:23	Zaytseva2	glycosylation profile	(none)	IgG3 with digalactosylated N-glycan structures (relative abundance) [%] mIgG3_G2 110054	CC	95	both	20-117wks	N=2	2018

Zaytseva2:24	Zaytseva2	glycosylation profile	(none)	IgG3 with sialylated N-glycan structures (relative abundance) [%] mIgG3_S 110055	CC	95	both	20-117wks	N=2	2018

Zaytseva2:25	Zaytseva2	glycosylation profile	(none)	IgG3 with monosialylated N-glycan structures (relative abundance) [%] mIgG3_S1 110056	CC	95	both	20-117wks	N=2	2018

Zaytseva2:26	Zaytseva2	glycosylation profile	(none)	IgG3 with disialylated N-glycan structures (relative abundance) [%] mIgG3_S2 110057	CC	95	both	20-117wks	N=2	2018

Zaytseva2:27	Zaytseva2	glycosylation profile	(none)	IgG3 with alpha1,3-linked galactose residue N-glycan structures (relative abundance) [%] mIgG3_aGal 110058	CC	95	both	20-117wks	N=2	2018